Pharma BD Deal Intelligence

UCB S.A. / Ra Pharmaceuticals, Inc.

2019 · Acquisition/Merger · $2.1B · Complete

The thesis fully played out: UCB's $48/share, ~$2.3B buy of Ra Pharmaceuticals bet on zilucoplan in Phase 3 for generalized myasthenia gravis, and it delivered — FDA approval as ZILBRYSQ landed October 17, 2023, the only once-daily, self-administered option in the class.

Outcome grade pending — assessed 5 years post-close.

Full analysis, sources & comparables →

The coverage arc

Oct 10, 2019 BioPharma Dive Bullish

UCB paid $48/share (93% premium) for Ra Pharma to bolt zilucoplan onto rozanolixizumab in gMG; Stifel modeled close to $2B peak sales and Jefferies over…

Oct 10, 2019 UCB (announcement) Bullish

UCB frames the acquisition of Ra Pharmaceuticals and lead asset zilucoplan as joining forces to improve treatment options for people living with myasthenia…

Apr 08, 2020 BioPharm International (completion) Bullish

CEO Jean-Christophe Tellier: 'This acquisition is a key part of this progress and an excellent strategic fit with UCB's strategy,' on completing the Ra…

Source summaries from our enrichment pipeline; follow links for originals.

All 9 sources with sentiment breakdown →

UCB acquired Ra Pharmaceuticals for $48/share in cash, a transaction valued at approximately $2.3 billion (EUR2.1 billion), announced October 10, 2019 and completed April 2, 2020. The lead asset, zilucoplan, is a once-daily subcutaneous, targeted peptide inhibitor of complement component 5 (C5), in pivotal Phase 3 (RAISE study) for generalized myasthenia gravis (gMG) at the time of the deal. The thesis fully played out: on October 17, 2023 the FDA approved zilucoplan as ZILBRYSQ for the treatment of adults with anti-acetylcholine receptor (AChR) antibody-positive gMG -- the only once-daily, self-administered gMG-targeted therapy -- and UCB launched it commercially in the U.S.

Did it work? Outcome assessment

Strategic verdict
Achieved Stated Rationale
Financial impact
Neutral
No impairment identified; Zilbrysq is in early launch ramp and UCB does not break out product-level sales, so revenue contribution versus the $2.1B price remains modest at the 5-year mark (>560 gMG patients on therapy by end-2024).
Pipeline outcome
Assets Advanced
Lead asset zilucoplan (Zilbrysq), a once-daily subcutaneous C5 complement inhibitor, won its first approval in Japan in September 2023, US FDA approval in October 2023, and EU approval in December 2023 for anti-AChR antibody-positive generalized myasthenia gravis, on the back of the positive Phase 3 RAISE study. Launches underway in US, Europe and Japan through 2024.

Key facts

Disease & market context

Generalized Myasthenia Gravis

$3.9B Soliris global revenue 1H 2019 annualized (gMG + PNH + aHUS)

Disease Overview

Generalized myasthenia gravis (gMG) is a rare autoimmune neuromuscular disorder in which autoantibodies (most commonly anti-AChR) disrupt neuromuscular transmission, causing fluctuating, fatigable weakness of ocular, bulbar, limb, and respiratory muscles. It is treatable but not curable; refractory patients face high morbidity and mortality from myasthenic crises.

Competitive Landscape

In 2019 the gMG treatment paradigm was shifting from chronic immunosuppression (steroids, azathioprine, mycophenolate, IVIG, plasmapheresis) toward targeted biologics. Alexion's Soliris (eculizumab, IV C5 inhibitor) had locked in ~1,200 US gMG patients and was the only FDA-approved targeted agent for AChR-Ab positive refractory gMG; its successor Ultomiris (ravulizumab, longer-acting C5) was poised to expand the franchise. Argenx's efgartigimod (FcRn antagonist, later approved as Vyvgart 2021) and Catalyst's Firdapse (3,4-DAP for LEMS — adjacent neuromuscular) were advancing. UCB itself was running rozanolixizumab (FcRn) in Phase 3, and acquiring Ra gave it zilucoplan — a once-daily subcutaneous self-injected C5 peptide — pairing two complementary mechanisms (FcRn + C5) inside one pipeline. The strategic logic: own both major non-IST mechanisms in gMG to capture switching, sequencing, and combination dynamics, while extending zilucoplan's optionality into IMNM, ALS (Healey platform), and other complement-driven rare diseases. Stifel modeled ~$2B peak sales and Jefferies >$1B, consistent with the 93% premium UCB paid. Both UCB assets ultimately reached approval (Vyvgart competed but UCB's Rystiggo and Zilbrysq launched 2023).

Deal timeline

Related deals — scored

DealYearValueOutcome
UCB S.A. / Ra Pharmaceuticals, Inc. (this deal)2019$2.1B
UCB S.A. / Candid Therapeutics, Inc.2026$2.2B
UCB S.A. / Zogenix Inc.2022$1.9B
UCB S.A. / Neurona Therapeutics, Inc.2026$1.1B
UCB S.A. / Antengene Corporation Limited2026$1.2B
Amgen Inc. / Immunex Corporation2002$16.0B92
PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG2017$1.3B88

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →